## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($247.16)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Gabelli Funds LLC Sells 5,582 Shares of Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T094554 | Somewhat-Bullish | Relevance: 99%
-  Gabelli Funds LLC reduced its stake in Labcorp Holdings Inc. ($LH) by 11.2% in the second quarter, selling 5,582 shares and now holding 44,103 shares valued at approximately $11.58 million. Company insiders, including CEO Adam H. Schechter and director Richelle P. Parham, also executed significant share sales. Despite these sales, Labcorp reported strong quarterly results, beating EPS estimates and announcing a quarterly dividend.

**2. 2Xideas AG Has $7.33 Million Holdings in Labcorp Holdings Inc. $LH**
- Source: MarketBeat | 20251209T082531 | Neutral | Relevance: 98%
-  2Xideas AG significantly reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 14.0% in the second quarter, bringing its total holdings to $7.33 million. Despite this, other institutional investors have recently shown increased interest in Labcorp shares, even as some analysts have adjusted price targets and ratings. The medical research company recently reported strong quarterly earnings, beating consensus estimates, and declared a quarterly dividend.

**3. Q3 Earnings Highlights: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks**
- Source: Finviz | 20251207T223200 | Neutral | Relevance: 74%
-  This article reviews the Q3 earnings of several testing & diagnostics services companies, focusing on RadNet (NASDAQ:RDNT). It highlights RadNet's strong revenue growth and exceeding analyst expectations, alongside the performance of competitors like Guardant Health, Labcorp, NeoGenomics, and Quest Diagnostics. The article also provides a brief market update, citing cooled inflation and a strong stock market performance in 2024.

**4. 1 Healthcare Stock with Impressive Fundamentals and 2 We Brush Off**
- Source: Markets Financial Content | 20251208T040915 | Neutral | Relevance: 73%
-  This article evaluates three healthcare stocks, recommending McKesson (MCK) due to its strong financials, market scale, and effective share repurchases. Conversely, Omnicell (OMCL) and Labcorp (LH) are identified as less attractive investments due to stagnant sales, declining margins, and increased costs. The analysis provides fundamental reasons for investors to consider buying McKesson while being cautious about Omnicell and Labcorp.

**5. Precision oncology at your community’s doorstep**
- Source: Illumina | 20251208T151032 | Somewhat-Bullish | Relevance: 70%
-  Illumina is making comprehensive genomic profiling (CGP) testing more accessible to community cancer care centers. This allows in-house labs to utilize CGP, which assesses hundreds of genes and biomarkers, to improve therapeutic options and patient outcomes. The move aims to decentralize CGP testing, reducing turnaround times and operational barriers for local oncology practices.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.4B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 14.7 |
| Current P/E | 15.8 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-1.0% over 5 days). Below STRENGTH zone by 6.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.00x) but short-term weakness (below SMA20). RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.14% (CS: 23) | Weak |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 0.960x | Below |
| vs SMA200 | 1.003x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $258.06
- **Stop Loss:** $247.16 (4.2% risk)
- **Target:** $268.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $6,967.62
- **Portfolio %:** 6.97%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*